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Edited by Alex TokerBreakpoint Cluster Region-Abelson kinase (BCR–Abl) is a
driver oncogene that causes chronic myeloid leukemia and a
subset of acute lymphoid leukemias. Although tyrosine kinase
inhibitors provide an effective treatment for these diseases,
they generally do not kill leukemic stem cells (LSCs), the
cancer-initiating cells that compete with normal hematopoietic
stem cells for the bone marrow niche. New strategies to target
cancers driven by BCR–Abl are therefore urgently needed. We
performed a small molecule screen based on competition be-
tween isogenic untransformed cells and BCR–Abl-transformed
cells and identified several compounds that selectively impair
the fitness of BCR–Abl-transformed cells. Interestingly,
systems-level analysis of one of these novel compounds, DJ34,
revealed that it induced depletion of c-Myc and activation of
p53. DJ34-mediated c-Myc depletion occurred in a wide range
of tumor cell types, including lymphoma, lung, glioblastoma,
breast cancer, and several forms of leukemia, with primary
LSCs being particularly sensitive to DJ34. Further analyses
revealed that DJ34 interferes with c-Myc synthesis at the level
of transcription, and we provide data showing that DJ34 is a
DNA intercalator and topoisomerase II inhibitor. Physiologi-
cally, DJ34 induced apoptosis, cell cycle arrest, and cell dif-
ferentiation. Taken together, we have identified a novel
compound that dually targets c-Myc and p53 in a wide variety
of cancers, and with particularly strong activity against LSCs.
Breakpoint Cluster Region-Abelson kinase (BCR–Abl) is
the driver mutation for chronic myeloid leukemia (CML) and
is also found in 25% to 30% of Philadelphia chromosome–
positive (Ph+) adult acute lymphoid leukemia (ALL) (1, 2).
CML and Ph+ ALL are effectively treated with tyrosine ki-
nase inhibitors (TKIs), such as imatinib. However,This article contains supporting information.
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BY license (http://creativecommons.org/licenses/by/4.0/).development of TKI resistance remains an issue, survival of
Ph+ ALL patients is suboptimal, and new treatment strate-
gies are required (3).
BCR–Abl activates downstream signaling pathways that
promote cell survival and proliferation and that inhibit dif-
ferentiation, such as the Ras–mitogen-activated protein kinase
and PI3K–Akt pathways (4). Another critical component of
the BCR–Abl network is the transcription factor c-Myc (5, 6),
which regulates genes important for proliferation and survival
and which is important for many types of hematological and
solid cancers (7).
Populations of self-renewing leukemic stem cells (LSCs)
generate the bulk of leukemic cells (8). LSCs are relatively
resistant to chemotherapy and persist as a potential source of
relapse, and drugs that eradicate LSCs may provide durable
remission. LSCs do not require BCR–Abl activity and are
therefore resistant to imatinib (9). However, they are highly
reliant on both c-Myc and p53, and dual targeting of both c-Myc
and p53 has been shown to selectively and synergistically elimi-
nate LSCs (6), demonstrating a need for novel compounds that
simultaneously inhibit c-Myc and activate p53.
LSCs compete with healthy hematopoietic stem cells for the
bone marrow niche, which constitutes a functional vulnera-
bility of primitive leukemia cells (10). However, cell competi-
tion is not typically assayed in high-throughput drug screens,
and drugs that reduce the competitiveness of cancer cells
without directly affecting cell viability are likely to be
discarded.
We reasoned that a straightforward cell competition assay,
in which healthy cells and isogenic oncogene-expressing
cells compete against each other, would efficiently identify
novel compounds that selectively target oncogene-
transformed cells. We identified several compounds that
preferentially inhibit BCR–Abl-transformed cells, including a
compound with anti-LSC activity that dually targets c-Myc/
p53.J. Biol. Chem. (2021) 296 100179 1
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Figure 1. Development of an isogenic cell competition–based drug screen to identify compounds that modulate the competitiveness of BCR–Abl-
expressing cells. A, effect of imatinib on the relative viability of WT or BCR–Abl-expressing Ba/F3 cells. Values of WT and BCR–Abl cells were normalized to
DMSO treatment in the presence of IL3 for WT and BCR–Abl cells, respectively. B, schematic overview of the competition-based drug assay. C, ratio of BCR–
Abl-expressing cells compared with WT cells following treatment with imatinib for 72 h. D, comparison of the selective targeting of BCR–Abl cells by
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High-throughput cell competition drug screen for BCR–Abl-
expressing cells
To identify novel compounds that target BCR–Abl-driven
leukemias, we developed an isogenic cell competition–based
drug screen by stably transfecting Ba/F3 cells with BCR–Abl.
Transfection of Ba/F3 cells with BCR–Abl transformed the
cells and resulted in interleukin-3 (IL3)–independent growth
(Fig. 1A). Consistent with previous reports (11, 12), BCR–Abl-
transformed cells were significantly more sensitive to imatinib
than WT cells, demonstrating they had become oncogene
addicted (Fig. 1A). Next, BCR–Abl-expressing cells were stably
transfected with enhanced GFP and WT cells with mCherry.
These cells were mixed and treated with imatinib for 72 h (all
experiments involving WT cells were performed in the pres-
ence of IL3 unless stated otherwise), after which the BCR–
Abl:WT cell ratio was measured by flow cytometry (Fig. 1B).
Imatinib conferred a competitive disadvantage on BCR–Abl
cells (Fig. 1C). Importantly, the competition assay was signif-
icantly more sensitive than the commonly used CellTiter-Glo
cell viability assay (Fig. 1D).
Using the competition assay, we screened 17,962 com-
pounds for selective inhibition of BCR–Abl-expressing cells
(Fig. 1E). Most compounds had little or no impact on the
BCR–Abl:WT cell ratio (Fig. 1F). We selected 203 compounds
that fell outside the 3σ interval (Fig. 1G). These compounds
were retested three times, resulting in 87 drugs that signifi-
cantly (p < 0.05) altered the BCR–Abl:WT cell ratio (Fig. 1H).
This included imatinib, thus validating the screen. All 87
compounds were subjected to dose–response tests with freshly
prepared drug stocks using competition assays and viability
assays. We found that some compounds did not replicate the
effect of the original library compounds (gray bars in Fig. 1H).
This may have been because of errors during preparation of
the original library, contaminants in the initial screen, or
compound degradation products. Nonreproducible com-
pounds and compounds that were excessively expensive to
synthesize were discarded, leaving a total of 13 compounds
that either increased (four compounds, although high doses
induced general toxicity; Fig. S1A) or decreased (eight com-
pounds; Fig. 2) the competitiveness of BCR–Abl-expressing
cells.
Compounds that increase the competitiveness of BCR–Abl-
expressing cells
Among the four compounds that promoted relative
competitiveness of BCR–Abl cells was the Janus kinase 2
(JAK2) inhibitor AZD1480 (Fig. S1A). Structurally unrelatedimatinib as measured using a cell viability assay or the competition assay. E,
screen. F, effect of different drugs on the competitiveness of BCR–Abl cells. Red
of tested compounds is displayed (approximately 20%). G, compounds that fe
for follow-up. H, the 87 compounds that were considered for follow-up studies
tests (see panel E). All values were normalized to DMSO. Gray bars represen
represent compounds with a reliable dose-dependent effect, which were selec
dependent effects but that were not selected for follow-up experiments, main
panels indicate standard deviation, and statistical significance was determined
epidermal growth factor receptor; IBMX, isobutylmethylxanthine; IL3, interleukJAK2 inhibitors had the same effect (Fig. S1B), whereas
cotreatment with imatinib restored the dependency of BCR–
Abl-expressing cells to JAK2 (Fig. S1C), consistent with pre-
vious studies (13).
The epidermal growth factor receptor (EGFR) inhibitors
lapatinib and gefitinib and the G protein–coupled receptor
inhibitor octoclothepin also promoted the competitiveness of
BCR–Abl cells (Fig. S1A), although the reasons for this are
currently unclear. Ba/F3 cells do not normally express EGFR,
suggesting an off-target effect of EGFR inhibitors, e.g., by
inhibiting JAK kinases (14). Octoclothepine inhibits G
protein–coupled receptors that elevate intracellular cAMP
levels (15), and cAMP impairs survival of BCR–Abl-expressing
cells (see later).
Compounds that reduce the competitiveness of BCR–Abl-
expressing cells
We identified eight compounds that reduced the competi-
tiveness of BCR–Abl cells, including sobuzoxane (topoisom-
erase II inhibitor) and the phosphodiesterase inhibitor
isobutylmethylxanthine (Fig. 2). Their effect was validated by
unrelated inhibitors (Fig. S2, A–E). Phosphodiesterase in-
hibitors increase cellular cAMP levels, which decrease the
growth rate of multiple tumor cell types by activating protein
kinase A (PKA) (16). The cAMP synthesis–activating agent
forskolin (16) also inhibited BCR–Abl cells, whereas the
inactive forskolin analog dideoxyforskolin had no effect
(Fig. S2, F–G). Similar results were obtained with the PKA
agonist 8Br-cAMP, but not with a cAMP analog that cannot
activate PKA (17) (Fig. S2, H–I). These data demonstrate that
drugs that increase cAMP levels selectively inhibit BCR–Abl-
expressing cells.
Six uncharacterized compounds selectively inhibited BCR–
Abl-expressing cells (DJ1, DJ2, DJ3, DJ12, DJ34, and DJ35;
Fig. 2), but they did not directly target BCR–Abl (Fig. S3).
Several of these compounds also inhibited the human CML
cell lines MEG-01, KU-812, and K562, as well as the human
Ph+ ALL cell line SD-1, which was not effectively killed by
imatinib (Fig. S4), indicating that these compounds may serve
as a starting point for development of alternative forms of
therapy for both CML and Ph+ ALL patients.
DJ34 selectively kills BCR–Abl-positive leukemia cells
We analyzed the drug-like properties of the novel com-
pounds using SwissADME (18) and found that DJ2, DJ12, and
DJ35 have unfavorable drug-like properties, whereas DJ1 and
DJ3 contain an alkyne group and a nitrile group, respectively,
which can be unstable and chemically reactive in vivo. DJ34
was predicted to have excellent drug-like properties (Table S2,schematic overview of the different stages of the competition-based drug
dots represent imatinib-treated cells. For display purposes, only a selection
ll outside the 3σ interval (compared with DMSO-treated cells) were selected
after rescreening of each compound in triplicate but prior to dose–response
t compounds that were nonreplicable and therefore removed. Green bars
ted for follow-up studies; blue bars represent compounds with reliable dose-
ly because of issues with availability and pricing. Error bars in the relevant
using Student’s t test. DMSO, dimethyl sulfoxide; EGFP, enhanced GFP; EGFR,
in-3; PDE, phosphodiesterase.
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*  p ≤0.01
** p ≤0.001
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Figure 2. Eight compounds that decreased the relative competitiveness of BCR–Abl-expressing cells compared with WT cells. Overview of the
names, known molecular targets and structures of the compounds, as well as the results obtained with the cell competition and cell viability assays. All
values were normalized to DMSO. Error bars indicate standard deviation, and statistical significance was determined using Student’s t test. DMSO, dimethyl
sulfoxide; IBMX, isobutylmethylxanthine; PDE, phosphodiesterase.
A novel topo II/c–Myc targeting compoundtab 1), which was confirmed by initial ADME (Absorption,
Distribution, Metabolism, and Excretion)–pharmacokinetic
(PK) analyses (Table S2, tab 2–6). We confirmed that freshly
synthesized DJ34 targeted BCR–Abl-transformed Ba/F3 cells4 J. Biol. Chem. (2021) 296 100179more efficiently than the isogenic parental cells (Fig. 3A). DJ34
also killed primary cancer cells derived from a Ph+ ALL pa-
tient more efficiently and at lower doses than imatinib
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Figure 3. DJ34 selectively targets BCR–Abl+ leukemia cells. A, BCR–Abl-transformed Ba/F3 cells are significantly more sensitive to DJ34 than isogenic
control cells. Cells were incubated with increasing concentrations of DJ34 for 72 h, after which cell viability was analyzed by CellTiter-Glo. B, DJ34 efficiently
kills primary Ph+ ALL cells. ALL cells were isolated from the bone marrow from a Ph+ ALL patient and incubated for 72 h with the indicated concentrations
of DJ34 (left) or imatinib (right), after which cell viability was analyzed as in panel A. C, primary ALL cells are more sensitive to DJ34 than bone marrow cells
derived from a healthy donor. Cells were isolated from bone marrow samples of an ALL patient (patient 10), a mixed B-ALL/AML patient (patient 14), and a
healthy donor and incubated for 72 h with the indicated concentrations of DJ34, after which relative cell viability was analyzed by CellTiter-Glo. Error bars
indicate standard deviation, and statistical significance was determined using Student’s t test. ALL, acute lymphoid leukemia; AML, acute myelocytic
leukemia; DMSO, dimethyl sulfoxide.
A novel topo II/c–Myc targeting compoundALL and mixed B-ALL/acute myelocytic leukemia (AML)
were more sensitive to DJ34 than healthy bone marrow cells
(Fig. 3C). Although analysis of a larger cohort of patients and
healthy donors is required, these data suggest the existence of
a potential therapeutic window.
DJ34 inhibits the c-Myc transcriptional program and activates
the p53 program
To better understand how DJ34 may inhibit cancer cells, we
first performed phosphoflow cytometry experiments to
investigate its effect on a panel of oncogenic signaling path-
ways. DJ34 had no effect on any of the examined phospho-
proteins (Fig. S5A). Phosphorylation of S473 of AKT and Y694
of Signal Transducer and Activator of Transcription 5, both of
which depend on BCR–Abl signaling, were also not affected by
DJ34 (Fig. S5B), consistent with our observations that DJ34does not directly inhibit BCR–Abl (Fig. S3). This shows that
DJ34 does not affect several canonical oncogenic pathways.
We then decided to apply a broader unbiased approach to
determine how DJ34 may affect cells using a combination of
RNA-Seq and MS-based phosphoproteomics for multipa-
rameter analysis of the cellular programs altered by DJ34
(Fig. 4A). RNA-Seq analysis identified 1206 and 1705 gene
transcripts that were at least twofold decreased or increased in
abundance by DJ34 treatment, respectively (Table S3). Gene
set enrichment analysis revealed that c-Myc–dependent genes
were significantly enriched in the RNA-Seq data set as well as
genes associated with the p53 pathway (Fig. 4B). Closer in-
spection confirmed that DJ34 downregulated genes, such as
EIF4, CD47, CDC2, CCND2, and RCC1, which are activated by
c-Myc (e.g., (19); Fig. 4C). Conversely, treatment with DJ34
promoted the expression of genes that are inhibited by c-Myc,J. Biol. Chem. (2021) 296 100179 5
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Figure 4. Multiparameter analysis to determine the effect of DJ34 on transcription and cell signaling. A, workflow for the combined phosphopro-
teomic and RNA-Seq analysis of BCR–Abl-expressing cells treated with 20 μM DJ34. B, gene set enrichment analysis of significantly upregulated and
downregulated transcripts following RNA-Seq, showing the top scoring enriched gene set terms. C, integrative genomics view of the mRNA levels of
A novel topo II/c–Myc targeting compound
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Figure 5. DJ34 targets c-Myc and p53 in a variety of cancer cells. Immunoblotting analysis for c-Myc, p53, and actin in various cancer cell lines treated
with DMSO or 20 μM DJ34 for 2 and 4 h. In addition, bone marrow cells derived from an acute myelocytic leukemia patient were treated with DMSO or DJ34
for 1, 2, and 4 h, and c-Myc and actin levels were analyzed by immunoblotting (patient 51, bottom right panel). DMSO, dimethyl sulfoxide.
A novel topo II/c–Myc targeting compoundsuch as NDRG1, CDKN1A, and GADD45 ((19, 20); Fig. 4C).
Similar findings were obtained by RT–quantitative PCR
(qPCR) analysis of several c-Myc target genes (Fig. 4D). Gene
Ontology analysis of the genes upregulated by DJ34 revealed a
significant enrichment of terms associated with reduced c-Myc
function and/or increased p53 signaling, such as mitotic cell
cycle, positive regulation of programmed cell death, and pos-
itive regulation of cell differentiation (Fig. S6A).
Phosphoproteomic analysis of cells treated with imatinib or
DJ34 indicated that these compounds have distinct effects on
cellular signaling pathways. We identified a similar number of
unique phosphopeptides from dimethyl sulfoxide (DMSO)-,
imatinib-, and DJ34-treated cells (Fig. S6B). Imatinib decreased
the abundance of several tyrosine-phosphorylated peptides,
including sites previously associated with BCR–Abl signaling
(thus validating our approach; Fig. 4E and Table S4), whereas
tyrosine phosphosites did not appear to be affected by DJ34selected c-Myc target genes. Y-axes show RFPKM values. Range of the respect
1000; RCC1: 0 to 1000; CDKN1A: 0 to 4500; GADD45A: 0 to 200; GADD45B: 0 to
genes after treatment with 20 μM DJ34. Error bars and standard deviation. E, v
proline-directed phosphophorylation sites affected by DJ34. G, volcano plots o
H, immunoblot analysis of BCR–Abl-expressing Ba/F3 cells treated with DMSO
enrichment analysis; qPCR, quantitative PCR; SE, single end.treatment (Table S5). Instead, a high proportion of the phos-
phosites reduced by DJ34 were proline-directed phosphosites
(Fig. 4F), including the residues Thr58 and Ser62 on c-Myc
(Fig. 4G), consistent with our RNA-Seq data indicating that
DJ34 inhibits c-Myc activity (Fig. 4, B–D).
Validation of RNA-Seq and MS data by immunoblotting
confirmed that not only phosphorylation of c-Myc Thr58 and
Ser62 was decreased by DJ34 but also showed that total c-Myc
protein levels were strongly reduced (Fig. 4H; total c-Myc
levels were not detected by MS, most likely because it is a
low-abundance protein that could only be detected after
enrichment of phosphorylated peptides). Furthermore, p53
was undetectable in the lysates of DMSO-treated cells,
whereas DJ34 treatment increased total p53 levels as well as
Ser15-phosphorylated p53 (a marker of active p53; Fig. 4H).
Together, these data indicate that DJ34 simultaneously inhibits
c-Myc and activates p53.ive y-axes: EIF4A1: 0 to 1500; CD47: 0 to 1500; CCND2: 0 to 2000; CDC2: 0 to
400; and NDRG1: 0 to 1000. D, RT–qPCR validation of selected c-Myc target
olcano plot showing phosphosites modulated by imatinib. F, proportions of
f two biological repeats showing phosphosites regulated by DJ34 treatment.
or 20 μM DJ34 for 2 and 4 h. DMSO, dimethyl sulfoxide; GSEA, gene set
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Figure 6. DJ34 intercalates the DNA and inhibits topo II but not topo I. A, RT–qPCR analysis of c-MYC mRNA levels after K562, MV4-11, HCT116, and
MIA–PaCa cells were treated with DMSO or 20 μM DJ34 for the indicated time points. mRNA levels were first normalized to GAPDH and then to the DMSO
treatment. B, schematic overview of c-MYC status in nontranslocated (WT) cells compared with the lymphoma cell lines CA46 and Raji, both of which
possess a reciprocal translocation between IgH and c-MYC. The translocation in CA46 cells leads to loss of the G4-quadruplex, whereas in Raji cells, the G4-
quadruplex is retained. C, immunoblot analysis of Raji and CA46 cells treated with DMSO or 20 μM DJ34 for 2 and 4 h. D, RT–qPCR analysis of c-MYC mRNA
levels in CA46 cells treated with DMSO or 20 μM DJ34 for 4 h. Primer pairs were designed to target exon 2 (as depicted above the bar graph), which almost
exclusively measures levels of the translocated c-MYC allele, because expression of the nontranslocated allele is approximately 1000-fold lower than the
A novel topo II/c–Myc targeting compound
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A novel topo II/c–Myc targeting compoundDJ34 induces depletion of c-Myc in a wide variety of tumor
types
A compound that both inhibits c-Myc while stabilizing p53
could provide a valuable therapeutic agent not only for leu-
kemia but also for a wide range of cancers (6, 21–23). We
found that DJ34 treatment resulted in c-Myc depletion in all
cancer cell lines tested, including glioblastoma, breast cancer,
and lung cancer cell lines (Fig. 5). DJ34 treatment depleted c-
Myc in primary human AML blasts as well (Fig. 5), showing
that the anti-c-Myc effect of DJ34 is not restricted to labora-
tory cell lines. Furthermore, DJ34 treatment increased p53
levels for almost all cancer cell lines that exhibited low p53
levels under control conditions (Fig. 5). This included the lung
cancer cell lines A-549 and H-460, the breast cancer cell line
MCF-7, and the glioblastoma cell line U-87, all of which ex-
press WT p53 (24). The same was observed for the leukemia
cell line SD-1 (unknown p53 status), whereas p53 was unde-
tectable in the p53-mutant CML cell line K562 (25). Two other
p53-mutant cell lines, H-1975 (R273H gain-of-function mu-
tation) and HCC-827 (V218DEL) (26, 27), exhibited high basal
p53 levels that were not increased by DJ34. Together, these
data show that DJ34 treatment broadly inhibits c-Myc levels
while at the same time activating p53.
DJ34-induced cellular depletion of c-Myc requires an intact
STIP1 homology and U-box containing protein 1/C-terminus
of HSC70-interacting pathway
We wished to better understand the cellular requirements
for the DJ34-induced reduction in c-Myc. The proteasomal
inhibitor MG132 prevented DJ34-induced c-Myc depletion
(Fig. S7A), suggesting that DJ34 treatment leads to proteaso-
mal depletion of c-Myc. In many cancers, proteasomal
degradation of c-Myc is prevented by increased phosphoryla-
tion of Ser62. This can occur via either hyperactive proline-
directed kinases, including mitogen-activated protein kinases
and cyclin-dependent kinases or inactivation of the phospha-
tase PP2A (28). DJ34 primarily downregulated proline-directed
phosphorylation sites (Fig. 4F), so we assessed whether DJ34
induces proteasomal depletion of c-Myc via regulating its
phosphorylation status. In vitro kinase analysis using the
KINOMEscan platform (www.discoverx.com) revealed that
DJ34 had moderate or no effect on the activity of 55 kinases
(Table S6), including the bona fide c-Myc kinases ERK and
Cdk2. In addition, pretreatment with the potent PP2A inhib-
itor okadaic acid did not prevent DJ34-induced depletion of c-
Myc (Fig. S7B; phosphorylation of the direct PP2A target Akt
is shown as control (29)). These data indicate that DJ34 doestranslocated allele (36). E, DNA intercalation/topo I inhibition assay showing th
detailed explanation of the assay). Supercoiled and relaxed plasmid substrates
after which the products were analyzed by agarose gel electrophoresis. The p
either relaxed (R) or supercoiled (Sc) form. F, DJ34 inhibits topo II. Supercoile
indicated above the figure, after which the products were analyzed by agarose
were used at 10 μM, except DJ34 which was used at 20 μM. G, illustration depic
PaCa cells (MIA–PaCa GPS–Myc). This cDNA lacks exon 1 and all introns. H, RT
treated with DMSO or 20 μM DJ34 for 4 h. Primers were designed targeting
between mRNA generated from WT c-MYC and cDNA-encoded c-MYC. CMV,
significant.not cause c-Myc depletion by targeting kinases or phospha-
tases known to regulate c-Myc proteasomal degradation.
We next tested the effect of DJ34 on other proteins known to
regulate c-Myc proteasomal degradation. Certain Skp, Cullin, F-
box (SCF) complexes can ubiquitinate c-Myc to target it for
destruction (28). SCF activity requires prior neddylation of the
Cullin RING ligase subunit by the ubiquitin-like protein Nedd8
(30). SCF activity can be efficiently inhibited by the small-
molecule inhibitor MLN4924, which targets the E1 Nedd8-
activating enzyme (31). While pretreatment of cells with
MLN4924 considerably increased c-Myc levels, DJ34 treatment
still resulted in depletion of a large proportion of c-Myc
(Fig. S7C). Treatment with DJ34 also induced strong c-Myc
depletion in FBXW7−/− cells (Fig. S7D), which lack F-box and
WD repeat domain-containing 7 (FBW7), which is a critical
component of the main SCF responsible for c-Myc degradation
(32).We did observe that the rate of c-Myc depletion was slower
in FBXW7−/− cells than in WT cells (see graph in Fig. S7D),
suggesting that part of the c-Myc pool might be degraded by
FBW7 on DJ34 treatment. Alternatively, it is possible that in
FBXW7−/− cells, the c-Myc degradation machinery is saturated
because of the high levels of basal c-Myc, resulting in an
apparent reduction in the rate of DJ34-induced c-Myc deple-
tion. Consistent with the latter hypothesis, the levels of the
FBW7 target cyclin E (33) were not affected by DJ34 (Fig. S7E),
arguing against the possibility that DJ34 directly activates the
SCFFBW7 complex to degrade c-Myc.
Next, we focused on CHIP (also known as STIP1 homology
and U-Box containing protein 1), which is an E3 ubiquitin ligase
that mediates c-Myc depletion independently of the phosphor-
ylation status of c-Myc. Strikingly, even after 6 h of DJ34 treat-
ment, CHIP−/−mouse embryo fibroblasts still had not succeeded
in degrading c-Myc (Fig. S7F), showing that an intact CHIP
pathway is required for depletion of c-Myc by DJ34.
DJ34 induces depletion of c-MYC mRNA
To further delineate the process of c-Myc depletion, we
combined DJ34 with the ribosome inhibitor cycloheximide and
monitored c-Myc protein levels over time. Interestingly, DJ34
did not appear to accelerate cycloheximide-induced depletion
of c-Myc (Fig. S7G), suggesting that DJ34 primarily acts up-
stream of the ribosome. We used qPCR to determine whether
DJ34 has a pretranslational effect on c-Myc, which revealed a
significant reduction in c-MYC mRNA levels on DJ34 treat-
ment in all cell lines tested, including K562, MV4-11, HCT-
116, and MIA–PaCa cells (Fig. 6A). These data suggest that
DJ34 inhibits transcription of c-MYC.at DJ34 intercalates the DNA but does not inhibit topo I (see Fig. S7I for a
were incubated with different compounds and purified topo I as indicated,
lasmid marker provided in the assay kit is the 4361 bp plasmid pBR322 in
d plasmid substrate was incubated with topo II and various compounds as
gel electrophoresis. Same plasmid marker was used as in (E). All compounds
ting the c-MYC cDNA sequence randomly integrated into the genome of MIA
–qPCR analysis of c-MYC mRNA levels after MIA–PaCa GFP–Myc cells were
different regions of c-MYC (depicted above each set of bars) to distinguish
cytomegalovirus; DMSO, dimethyl sulfoxide; EGFP, enhanced GFP; ns, not
J. Biol. Chem. (2021) 296 100179 9
A novel topo II/c–Myc targeting compoundThe reduction in c-MYCmRNA levels by DJ34 could be due
to altered mRNA stability rather than inhibition of transcrip-
tion. To distinguish between these possibilities, we blocked
transcription with the strong RNA polymerase II inhibitor α-
amanitin (34). We hypothesized that if DJ34 destabilizes
mRNA, combining DJ34 with α-amanitin should result in
more rapid loss of c-Myc, whereas there should be no added
effect if DJ34 impedes c-MYC transcription, because mRNA
synthesis is already fully blocked by α-amanitin. While treat-
ment with α-amanitin resulted in efficient removal of c-Myc,
α-amanitin did not appear to potentiate DJ34-induced loss of
c-Myc (Fig. S7H), indicating that DJ34 and α-amanitin target
the same process, i.e., c-MYC transcription.
We reasoned that DJ34 might inhibit c-MYC transcription by
interacting with regulatory elements in the c-MYC gene, such as
the G-quadruplex in the promoter region (G4). This is a helical
DNA structure formed by guanine tetrads, and several com-
pounds can stabilize the quadruplex to inhibit c-MYC tran-
scription (35). We examined c-Myc protein levels in two
lymphoma cell lines in which genomic translocations of IgHwith
c-MYC have resulted in loss of the c-MYC promoter, either
retaining or losing the G4-quadruplex (Raji and CA46, respec-
tively; Fig. 6B) (36). DJ34 treatment downregulated c-Myc in
both cell lines, suggesting that DJ34 does not require the G4-
quadruplex to inhibit c-MYC transcription (Fig. 6C). RT–qPCR
experiments with CA46 cells confirmed that DJ34 treatment
resulted in a strong reduction in c-MYC mRNA (Fig. 6D).
Together, these data show that DJ34 inhibits transcription of c-
MYC and that this occurs independently of the G4-quadruplex.DJ34 intercalates DNA and inhibits topoisomerase II but not
topoisomerase I
DJ34 contains three planar aromatic rings, a feature often
found in DNA-intercalating compounds. Furthermore, com-
pounds that inhibit topoisomerases through DNA intercala-
tion have been shown to reduce c-MYC transcription (37,38).
We therefore tested whether DJ34 intercalates and/or inhibits
topoisomerase (topo) I/II to block c-MYC transcription. First,
we performed a topo I DNA unwinding/intercalation assay, in
which compounds are incubated with either a supercoiled or a
relaxed substrate plasmid in the presence of topo I (see Fig. S7I
for an overview). We found that incubation of DJ34 with topo I
and either a supercoiled or a relaxed plasmid substrate
exclusively produced supercoiled plasmids, showing that DJ34
does indeed intercalate but does not inhibit topo I (Fig. 6E;
lanes 5 and 12). Notably, DJ34 intercalated at lower concen-
trations than m-amsacrine, a known DNA intercalator used to
treat ALL (compare lanes 4–5 with lanes 6–7 and lanes 11–12
with lanes 13–14).
We then performed a topo II relaxation assay based on a
supercoiled plasmid substrate that is relaxed by topo II, using
m-amsacrine and doxorubicine (topo II poisons), 4,4'-(1,2-
Dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (also known
as ICRF-193, a topo II catalytic inhibitor), and irinotecan (topo
I inhibitor with no effect on topo II) as controls. This revealed
that DJ34 is a potent inhibitor of topo II, producing a strong10 J. Biol. Chem. (2021) 296 100179supercoiled band on the DNA gel similar to that observed
for 4,4'-(1,2-Dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione
(Fig. 6F; lanes 3 and 8, respectively). The DJ34 analog acridine
did not inhibit topo II, suggesting specificity of DJ34, and
determining the relevant molecular features of DJ34 is the
focus of an ongoing follow-up study. Collectively, these data
demonstrate that DJ34 is a DNA intercalator and a strong
inhibitor of topo II, but not topo I.
It has previously been shown that intron 1 of the c-MYC gene
contains a sequence that reduces c-MYC transcription because
of torsional tension that arises during transcription, and the
activity of topo II is essential for relieving this tension and
maintaining high levels of c-MYC transcription; indeed,
expression of plasmid-encoded c-MYC complementary DNA
lacking this intron does not require topo II activity (37–40). We
analyzed c-Myc levels in theMIA–PaCaGPS–Myc cell line (41),
which contains the endogenous WT c-MYC alleles in addition
to a randomly integrated dsRED–IRES–GFP–c-MYC construct
(Fig. 6G). This c-MYC complementary DNA lacks all introns
including the aforementioned transcription-reducing intron 1,
which is targeted by topo II to promote high c-MYC expression
(37–40). Interestingly, analysis of mRNA levels by RT–qPCR
revealed that although endogenous c-MYC mRNA levels were
strongly reduced, transcription of GFP–c-MYC was completely
resistant to DJ34 (Fig. 6H). Taken together, although the precise
mechanism remains to be unraveled, these data are consistent
with a model in which DNA intercalation by DJ34 poisons topo
II to interfere with c-MYC transcription.
DJ34 induces cell cycle arrest, cell differentiation, and
apoptosis
We next investigated the physiological consequences of DJ34
treatment. Flow cytometry analysis showed that DJ34 treatment
resulted in G1/G0 cell cycle arrest and apoptosis (Fig. 7A),
which was confirmed by poly(ADP-ribose) polymerase cleavage
in multiple cancer cell lines (Fig. 7B and Fig. S7J). In addition to
causing apoptosis and cell cycle arrest, we found that DJ34
increased the expression levels of the differentiation marker
CD25 while decreasing the levels of CD43, a marker of undif-
ferentiated hematopoietic progenitors (Fig. 7C). DJ34 appeared
to be more effective at inducing cell differentiation than ima-
tinib, which is important, because c-Myc is known to mediate
imatinib resistance by preventing imatinib-induced cell differ-
entiation (42), and preventing differentiation is one of the
mechanisms by which c-Myc promotes drug resistance in
leukemia (43). Collectively, these data indicate that DJ34 trig-
gers apoptosis, cell cycle arrest, and differentiation.
DJ34 has anti-LSC activity
LSCs mediate disease relapse, and novel therapy that erad-
icates LSCs is expected to provide durable remission (44). It
was previously shown that inhibiting c-Myc and reactivating
p53 is an effective approach to eradicate LSCs (6). Given that
DJ34 has dual c-Myc- and p53-targeting activity, we analyzed
the effect of DJ34 on LSCs. We isolated bone marrow cells
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Figure 7. DJ34 induces cell cycle arrest, apoptosis, and differentiation. A, cell cycle analysis of Ba/F3-BCR–Abl cells treated with DMSO or 20 μM DJ34 for
24 and 48 h. B, immunoblot analysis of K562 and MV4-11 cells treated with DMSO or 20 μM DJ34 at the indicated concentrations for 48 h using antibodies
against PARP and actin. C, analysis by flow cytometry of the differentiation marker CD25 and the hematopoietic progenitor cell marker CD43 after treatment
of Ba/F3-BCR–Abl cells with either 10 μM imatinib or 20 μM DJ34. About 10,000 cells were counted for each treatment and time point. D, CD34+CD38− LSCs
are particularly sensitive to DJ34. Mononuclear cells were isolated from the bone marrow of a Ph+ CML patient and incubated for 24 h with 10 μM DJ34,
after which the fraction of CD34+ CD38− cells in the total cell pool was analyzed by flow cytometry. Error bars and standard deviation. E, schematic
overview of the findings of this study. DJ34 intercalates the DNA and inhibits topo II to activate p53 and to block transcription of c-MYC, which tentatively
occurs in intron 1. c-Myc protein is then ubiquitinated and degraded by the proteasome through a pathway that requires CHIP. APC, anaphase promoting
complex; DMSO, dimethyl sulfoxide; PARP, poly(ADP-ribose) polymerase-1.
A novel topo II/c–Myc targeting compoundwith 10 μM DJ34. After 48 h, we analyzed the relative number
of LSCs in the total cell population by flow cytometry.
Importantly, DJ34 significantly reduced the relative number of
CD34+ CD38− LSCs in the total pool of bone marrow–derived
cancer cells (Fig. 7D), showing that LSCs are particularly
sensitive to DJ34.Discussion
We performed a cell competition drug screen and identified
several compounds that selectively inhibitBCR–Abl-expressingcells
but not isogenic control cells. None of these compounds functioned
as TKIs, suggesting they target parallel pathways that control pro-
liferation and survival of transformed cells. Our findings supportJ. Biol. Chem. (2021) 296 100179 11
A novel topo II/c–Myc targeting compoundprevious studies that showed that isogenic cell competition screens
provide a powerful alternative approach to traditional cell viability–
based drug screens, facilitating the identification of compounds that
induce cell cycle arrest and cellular differentiation, as well as those
that induce apoptosis. It has been argued that such phenotypic drug
screens may help reduce the high attrition rates that have charac-
terized drug development in the past decade (45, 46).
We identified a compound that may provide an effective
lead structure for therapy. A model of our findings is shown in
Figure 7E. DJ34 is a DNA intercalator and inhibits topo II,
resulting in activation of p53 and inhibition of c-MYC tran-
scription. As demonstrated by RNA-Seq, DJ34 did not appear
to broadly inhibit transcription and showed relative selectivity
for c-MYC, as the main genes affected by DJ34 were c-MYC
itself and c-Myc target genes. The exact DNA sequence
recognized by DJ34 remains to be identified, and exactly how
DJ34 activates p53 remains to be established, but it is likely
similar to activation of p53 by other topo II poisons.
DJ34-induced depletion of c-Myc was independent of the
phosphorylation status of c-Myc. This is important because c-
Myc–addicted tumors often stabilize c-Myc by interfering with
its phosphorylation (47). Therefore, DJ34-based treatments may
show clinical efficacy toward a broad range of c-Myc–addicted
cancers, including cancers driven by oncogenic c-Myc mutants,
such as the c-Myc-T58 and c-Myc-P57 mutations that are often
found in Burkitt’s lymphoma and which are refractory to phos-
phoregulation (48). Furthermore, DJ34 overcame MLN4924-
dependent stabilization of c-Myc, suggesting that DJ34 induces
c-Myc depletion independently of SCF ubiquitin ligases. This
provides a therapeutic advantage because SCFs are oftenmutated
and inactivated in cancer, including ALL (32, 49, 50). Indeed, loss
of FBXW7 has been shown to bolster leukemia-initiating stem
cells in ALL by increasing c-Myc abundance, and inhibition of c-
Myc resulted in remission in fbxw7-mutant mouse models of
ALL (51). We believe that DJ34, or its derivatives, may therefore
be particularly effective in these forms of ALL. We are currently
testing the efficacy of DJ34 inmousemodels, and our preliminary
data indicate that DJ34 has a favorable ADME/Tox profile and is
well tolerated by animals, all of which will be reported elsewhere.
c-Myc induces stemness and blocks cellular senescence and
differentiation in many forms of cancer and promotes LSC
survival in leukemia. Brief or even partial suppression of c-Myc
can result in acute and sustained tumor regression, and dual
targeting of p53 and c-Myc is a particularly effective strategy to
kill LCSs (6). However, development of drugs that inhibit c-
Myc has progressed slowly, primarily because c-Myc is widely
considered undruggable. Given that DJ34 has potent anti-c-
Myc activity in a broad range of cancers, that it can simulta-
neously activate p53, and that LSCs are particularly sensitive to
DJ34, we believe it forms an excellent starting point for further
development of anti-c-Myc cancer therapy.
Experimental procedures
Cell culture
Suspension cells (Ba/F3, K-562, MEG-01, MV4-11, SD-1,
CA46, Raji, Daudi, 697, RS411, and KU-812) were cultured12 J. Biol. Chem. (2021) 296 100179with RPMI-1640 with 10% fetal serum albumin and 1% peni-
cillin/streptomycin. WT Ba/F3 cells also received 7.5 ng/ml
IL3. Adherent cells (MIA PaCa, MIA–PaCa, GPS-Myc, A549,
H460, MCF7, U87, HCC-827, H1975, SKBR3, MRC5, A375,
MEWO, SK-MEL28, WM1366, HCT116, mouse embryo fi-
broblasts, and LN229) were cultured in Dulbecco’s modified
Eagle’s medium with 10% fetal serum albumin and 1% peni-
cillin/streptomycin. Primary patient cells were cultured with
mononuclear cell basal medium (PromoCell, Heidelberg,
Germany) supplemented with 10% SupplementMix (Promo-
Cell, Heidelberg, Germany).
Cell competition–based drug screen
Compounds were diluted in 10% DMSO and dispensed at
the Chemical Biology Screening Platform of the Nordic Centre
for Molecular Medicine (Oslo, Norway) into individual wells of
a 384-well plate using an Echo acoustic liquid dispenser
(Labcyte, San Jose, CA, USA) such that, after addition of cells,
the compound concentration was 5 μM. Drug libraries that
were used were the Sigma LOPAC1280 library and the
ChemBioNet drug library (52).
A total of 1500 cells were mixed at a BCR–Abl:WT cell ratio
of 1.3:1 in 50 μl cell culture medium (containing IL3). This
ratio accounted for the slower growth rate of cells transfected
with BCR–Abl and ensured that the ratio after 72 h treatment
with DMSO was 1:1. In addition to library compounds, ima-
tinib (5 μM) was used as a positive control in 16 wells of each
384-well plate. After 72 h, the number of GFP-positive (BCR–
Abl) and red fluorescent protein–positive (WT) cells in each
well was recorded by flow cytometry and used to calculate a
cell ratio. The rationale for using 72 h was that during the
course of our experiments we observed that in the presence of
most drugs the cells had undergone at least several doublings
after this amount of time (unperturbed Ba/F3 cells have a
doubling time of approximately 12 h), which is essential for
identifying a potential in vitro therapeutic index.
Chemical synthesis
Synthesis of DJ34 and other compounds was performed by
Hit2Lead, ChemBridge, Cambridge, UK. DJ34 is available on
request.
RNA-Seq
RNA-Seq was performed as previously described (53); see
Supporting information section.
RT–qPCR
RT–qPCR experiments were performed as previously
described (54); see Supporting information section.
In vitro kinase assays
Kinase assays were performed using the Omnia Kinase
Assay according to the manufacturer’s protocol (Life Tech-
nologies, Carlsbad, CA, USA); see Supporting information
section.
A novel topo II/c–Myc targeting compoundProteomic and phosphoproteomic analyses
MS experiments were performed as previously described
(55), see Supporting information section.
Flow cytometry and phosphoflow cytometry
Flow cytometry was performed as previously described (56).
See Supporting information section.
Differentiation analysis
Bcr/Abl-expressing Ba/F3 cells were treated with DMSO,
10 μM imatinib, or 20 μM DJ34 for 24, 48, and 72 h. Cells
were fixed as described previously (see cell cycle analysis),
incubated with allophycocyanin-conjugated mouse anti-
CD-25 and CD-43 antibodies (BD Biosciences, San Jose,
CA, USA) and analyzed by flow cytometry for surface
expression of CD25 and CD43.
Apoptosis analysis
BCR–Abl-expressing Ba/F3 cells were treated with DMSO,
10 μM imatinib, and 20 μM DJ34 for 24, 48, and 72 h. Samples
were then analyzed by flow cytometry, and cells undergoing
apoptosis were quantified/gated according to changes in
morphological and physical properties using forward and side-
scattered light.
Western blotting
Western blotting was performed as previously described
(17); see Supporting information section.
ADME–PK analysis
ADME–PK analysis was outsourced to the public CRO
Cyprotex (www.cyprotex.com).
DNA intercalation and topoisomerase assays
DNA intercalation and topoisomerase I and II activity assays
were performed using a DNA Unwinding Assay Kit and a
Human Topoisomerase II Relaxation Assay Kit, respectively, as
described in the user manual (Inspiralis, Norwich, UK).
Patient information
Patient 10—Caucasian male, ALL; patient 13—Caucasian
male, Ph+ ALL; patient 14—Caucasian female, AML; patient
45—Caucasian male, CML.
Data availability
All data are contained within the article, except RNA-Seq
and MS data sets, which were deposited in the following pub-
lic repositories: RNA-Seq data were deposited at Gene
Expression Omnibus (GSE100678); MS data were deposited to
the ProteomeXchange Consortium via Proteomics IDEntifica-
tions Database (PRIDE) repository (PXD018812). In addition,
MS spectra were deposited to MS-Viewer (57). The search keys
for these data sets are: ocnteamqeu (imatinib phosphoproteo-
mic data); agzbem8ayy (imatinib proteomic data); p0kpemrznrand aeqwowtaj8 (DJ34 phosphoproteomic data repeats 1 and 2,
respectively); and ijxqqn8lyw (DJ34 proteomic data).
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